Merck sees potential U.S. authorization for COVID-19 antiviral before year-end

(Reuters) – Drugmaker Merck & Co Inc (MRK.N) said on Monday it sees potential U.S. emergency use authorization for its experimental COVID-19 antiviral treatment, molnupiravir, before year-end.

“I would just say that our program is enrolling well, and we expect to be able to see clinical data in the back half of the year,” Merck’s Chief Executive Officer Robert Davis said at Morgan Stanley’s Annual Global Healthcare Conference.

Merck and partner Ridgeback Biotherapeutics are conducting a late-stage trial of molnupiravir in non-hospitalized COVID-19 patients to see if it reduces the risk of hospitalization or death. read more

The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo

Merck in June said it expected to file for the emergency use authorization of molnupiravir in the second half of 2021 at the earliest. read more

Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber

Our Standards: The Thomson Reuters Trust Principles.


Reuters source: